Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma

Patricia A. Henry, Sergei P. Atamas, Vladimir V. Yurovsky, Irina Luzina, Fredrick Wigley, Barbara White

Research output: Contribution to journalArticle

Abstract

Objective. To examine domain recognition by anti-DNA topoisomerase I (anti-DNA topo I, or anti-topo I) antibodies over time in scleroderma patients. Methods. Serial serum samples from scleroderma patients with known reactivity to Scl-70, a 70-kd topo I breakdown product, were tested by immunoblot for IgM, IgG, IgA, κ, and λ reactivity to Scl-70 and 8 overlapping recombinant peptide fragments (F1-F8) that span the human topo I molecule. Results. IgM, IgG, κ, and λ anti-topo I antibodies in both early-disease and late-disease serum samples preferentially recognized the Scl-70 molecule rather than the F1-F8 peptides, suggesting preferential recognition of conformational determinants on Scl-70 throughout the disease course. Amounts of both primary and secondary anti-topo I antibodies to Scl-70 varied over time, including increases in primary antibody responses late in the disease course. Striking variability in recognition of the F1-F8 peptides by IgM, IgG, IgA, κ, and λ anti-topo I antibodies was seen in serial samples. Most often, the change in F1-F8 recognition from one sample to the next was unpredictable, although occasionally patterns of antibody recognition were reciprocal in serial samples. Of note, in several patients, what could have been interpreted as domain spreading among F1-F8 in 2 successive samples was just a part of changing antibody reactivity to these peptides that again became more restricted in a third sample. Conclusion. Titers and immunodominant domains recognized by both primary and secondary anti-topo I antibodies are highly variable over time. This suggests continual antigen presentation and regulation of the anti-topo I antibody response in scleroderma, even late in the disease course.

Original languageEnglish (US)
Pages (from-to)2733-2742
Number of pages10
JournalArthritis and Rheumatism
Volume43
Issue number12
DOIs
StatePublished - 2000

Fingerprint

Type I DNA Topoisomerase
Autoantibodies
Antibodies
Peptides
Antibody Formation
Immunoglobulin M
Immunodominant Epitopes
Peptide Fragments
Antigen Presentation
Serum
Immunoglobulin A
Immunoglobulin G
DNA

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma. / Henry, Patricia A.; Atamas, Sergei P.; Yurovsky, Vladimir V.; Luzina, Irina; Wigley, Fredrick; White, Barbara.

In: Arthritis and Rheumatism, Vol. 43, No. 12, 2000, p. 2733-2742.

Research output: Contribution to journalArticle

Henry, Patricia A. ; Atamas, Sergei P. ; Yurovsky, Vladimir V. ; Luzina, Irina ; Wigley, Fredrick ; White, Barbara. / Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma. In: Arthritis and Rheumatism. 2000 ; Vol. 43, No. 12. pp. 2733-2742.
@article{b7b99811296c429bb9beae45ba0ffcd5,
title = "Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma",
abstract = "Objective. To examine domain recognition by anti-DNA topoisomerase I (anti-DNA topo I, or anti-topo I) antibodies over time in scleroderma patients. Methods. Serial serum samples from scleroderma patients with known reactivity to Scl-70, a 70-kd topo I breakdown product, were tested by immunoblot for IgM, IgG, IgA, κ, and λ reactivity to Scl-70 and 8 overlapping recombinant peptide fragments (F1-F8) that span the human topo I molecule. Results. IgM, IgG, κ, and λ anti-topo I antibodies in both early-disease and late-disease serum samples preferentially recognized the Scl-70 molecule rather than the F1-F8 peptides, suggesting preferential recognition of conformational determinants on Scl-70 throughout the disease course. Amounts of both primary and secondary anti-topo I antibodies to Scl-70 varied over time, including increases in primary antibody responses late in the disease course. Striking variability in recognition of the F1-F8 peptides by IgM, IgG, IgA, κ, and λ anti-topo I antibodies was seen in serial samples. Most often, the change in F1-F8 recognition from one sample to the next was unpredictable, although occasionally patterns of antibody recognition were reciprocal in serial samples. Of note, in several patients, what could have been interpreted as domain spreading among F1-F8 in 2 successive samples was just a part of changing antibody reactivity to these peptides that again became more restricted in a third sample. Conclusion. Titers and immunodominant domains recognized by both primary and secondary anti-topo I antibodies are highly variable over time. This suggests continual antigen presentation and regulation of the anti-topo I antibody response in scleroderma, even late in the disease course.",
author = "Henry, {Patricia A.} and Atamas, {Sergei P.} and Yurovsky, {Vladimir V.} and Irina Luzina and Fredrick Wigley and Barbara White",
year = "2000",
doi = "10.1002/1529-0131(200012)43:12<2733::AID-ANR13>3.0.CO;2-G",
language = "English (US)",
volume = "43",
pages = "2733--2742",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma

AU - Henry, Patricia A.

AU - Atamas, Sergei P.

AU - Yurovsky, Vladimir V.

AU - Luzina, Irina

AU - Wigley, Fredrick

AU - White, Barbara

PY - 2000

Y1 - 2000

N2 - Objective. To examine domain recognition by anti-DNA topoisomerase I (anti-DNA topo I, or anti-topo I) antibodies over time in scleroderma patients. Methods. Serial serum samples from scleroderma patients with known reactivity to Scl-70, a 70-kd topo I breakdown product, were tested by immunoblot for IgM, IgG, IgA, κ, and λ reactivity to Scl-70 and 8 overlapping recombinant peptide fragments (F1-F8) that span the human topo I molecule. Results. IgM, IgG, κ, and λ anti-topo I antibodies in both early-disease and late-disease serum samples preferentially recognized the Scl-70 molecule rather than the F1-F8 peptides, suggesting preferential recognition of conformational determinants on Scl-70 throughout the disease course. Amounts of both primary and secondary anti-topo I antibodies to Scl-70 varied over time, including increases in primary antibody responses late in the disease course. Striking variability in recognition of the F1-F8 peptides by IgM, IgG, IgA, κ, and λ anti-topo I antibodies was seen in serial samples. Most often, the change in F1-F8 recognition from one sample to the next was unpredictable, although occasionally patterns of antibody recognition were reciprocal in serial samples. Of note, in several patients, what could have been interpreted as domain spreading among F1-F8 in 2 successive samples was just a part of changing antibody reactivity to these peptides that again became more restricted in a third sample. Conclusion. Titers and immunodominant domains recognized by both primary and secondary anti-topo I antibodies are highly variable over time. This suggests continual antigen presentation and regulation of the anti-topo I antibody response in scleroderma, even late in the disease course.

AB - Objective. To examine domain recognition by anti-DNA topoisomerase I (anti-DNA topo I, or anti-topo I) antibodies over time in scleroderma patients. Methods. Serial serum samples from scleroderma patients with known reactivity to Scl-70, a 70-kd topo I breakdown product, were tested by immunoblot for IgM, IgG, IgA, κ, and λ reactivity to Scl-70 and 8 overlapping recombinant peptide fragments (F1-F8) that span the human topo I molecule. Results. IgM, IgG, κ, and λ anti-topo I antibodies in both early-disease and late-disease serum samples preferentially recognized the Scl-70 molecule rather than the F1-F8 peptides, suggesting preferential recognition of conformational determinants on Scl-70 throughout the disease course. Amounts of both primary and secondary anti-topo I antibodies to Scl-70 varied over time, including increases in primary antibody responses late in the disease course. Striking variability in recognition of the F1-F8 peptides by IgM, IgG, IgA, κ, and λ anti-topo I antibodies was seen in serial samples. Most often, the change in F1-F8 recognition from one sample to the next was unpredictable, although occasionally patterns of antibody recognition were reciprocal in serial samples. Of note, in several patients, what could have been interpreted as domain spreading among F1-F8 in 2 successive samples was just a part of changing antibody reactivity to these peptides that again became more restricted in a third sample. Conclusion. Titers and immunodominant domains recognized by both primary and secondary anti-topo I antibodies are highly variable over time. This suggests continual antigen presentation and regulation of the anti-topo I antibody response in scleroderma, even late in the disease course.

UR - http://www.scopus.com/inward/record.url?scp=0034543315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034543315&partnerID=8YFLogxK

U2 - 10.1002/1529-0131(200012)43:12<2733::AID-ANR13>3.0.CO;2-G

DO - 10.1002/1529-0131(200012)43:12<2733::AID-ANR13>3.0.CO;2-G

M3 - Article

C2 - 11145031

AN - SCOPUS:0034543315

VL - 43

SP - 2733

EP - 2742

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -